Oveporexton
InvestigationalAlso known as: TAK-861
A first-in-class oral orexin receptor 2 (OX2R) selective agonist developed by Takeda for narcolepsy type 1. Though not a peptide itself, oveporexton restores orexin peptide signaling lost due to autoimmune destruction of orexin-producing neurons. Phase 3 trials demonstrate significant reductions in excessive daytime sleepiness and cataplexy, with FDA Breakthrough Therapy designation.
Research Statistics
Takeda TAK-861 with Phase 3 narcolepsy trials, FDA Breakthrough Therapy designation, and 22 human studies; OX2R selective agonist mechanism is well-characterized in orexin neuroscience.
Research Dossier
Overview
What is Oveporexton and what does the research say?
Mechanism of Action
Oveporexton is a first-in-class selective orexin receptor 2 (OX2R) agonist that restores the missing orexin signal in narcolepsy type 1 patients.
How It Works (Simplified)
Oveporexton replaces the missing orexin signal through targeted receptor activation:
Selectively binds and activates orexin receptor 2 in key arousal centers, mimicking the effect of endogenous orexin peptides.
Activates wake-promoting neurons in TMN, locus coeruleus, and VTA, releasing histamine, norepinephrine, and dopamine.
Restores clear boundaries between sleep and wakefulness, reducing inappropriate sleep intrusions during the day.
Suppresses REM sleep intrusions that cause cataplexy, the sudden muscle weakness triggered by emotions in NT1.
Scientific Pathways
OX2R-Gq/11 Signaling Pathway (Wake Promotion)
Oveporexton → OX2R binding → Gq/11 activation → PLC → IP3 + DAG → Ca2+ release + PKC
↓
Neuronal depolarizationArousal Center Cascade (Neurotransmitter Release)
OX2R activation → TMN (histamine) + LC (norepinephrine) + VTA (dopamine) → Stable wakefulnessKey Research: Sakurai et al. (Cell 1998) discovered orexins and their receptors. PMID:9491897
Important Limitations
- Oveporexton is NOT a peptide; it is a small molecule that modulates the orexin peptide system
- Currently investigational - not yet approved by FDA or other regulatory agencies
- Efficacy in narcolepsy type 2 (normal CSF orexin) is still being evaluated
- Long-term safety data beyond clinical trial duration is pending
- Head-to-head comparative trials vs sodium oxybate not yet completed
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on Phase 2/3 data: Rapid onset of wake-promoting effects. Patients may notice reduced daytime sleepiness within first weeks. Cataplexy frequency begins to decrease.
Continued improvement in wakefulness measures. Phase 3 endpoints assessed at multiple timepoints showed progressive benefit. Optimal steady-state drug levels achieved.
Full therapeutic effects observed in clinical trials. ESS improvements stabilize. Cataplexy reduction maintained at approximately 70-80% from baseline.
Long-term extension studies (NCT04950842) ongoing to assess durability. Preliminary data suggests sustained efficacy. Safety monitoring continues.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Oveporexton product quality
Good Signs (5 indicators)
Warning Signs (4 indicators)
Bad Signs (5 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Oveporexton with other peptides. Based on published research and mechanistic considerations.
Orexin-A
SynergisticOveporexton mimics the endogenous orexin peptide signal at OX2R. In narcolepsy type 1, where orexin-A is deficient, oveporexton provides replacement receptor activation.
Orexin-B
SynergisticOrexin-B preferentially activates OX2R, the same target as oveporexton. The drug compensates for lost orexin-B signaling in NT1 patients.
Modafinil
CompatibleDifferent wake-promoting mechanisms (dopamine/NE modulation vs OX2R agonism). May be used in combination, though oveporexton alone may be sufficient.
Pitolisant
CompatibleH3 receptor antagonist with different mechanism. Potential for complementary wake promotion, though clinical combination data is limited.
Suvorexant
AvoidSuvorexant is a dual orexin receptor antagonist (DORA) used for insomnia. Concurrent use would cause direct pharmacological antagonism, negating therapeutic effects.
Lemborexant
AvoidLemborexant is a DORA for insomnia. Combining with oveporexton would result in opposing receptor effects and is contraindicated.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Oveporexton
Related Peptides
Alixorexton
ALKS 2680, ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Cerebrolysin
FPF-1070, N-PEP-12, Renacenz
A porcine brain-derived peptide mixture approved in over 50 countries (Austria, Russia, China, Germany) for stroke, dementia, and traumatic brain injury. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. NOT FDA-approved despite decades of international use. Mixed Phase 3 results but positive meta-analyses and widespread clinical adoption in Europe, Asia, and Latin America.
Cerluten
Brain cytamin, Cerebral peptides, A-5 brain peptides
A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Cortexin
Cortexinum, Polypeptide brain extract, Bovine brain cortex polypeptides
A Russian neuropeptide complex derived from porcine or bovine cerebral cortex, approved in Russia and CIS countries for neurological conditions. Contains low molecular weight polypeptides (1,000-10,000 Da) with proposed neurotrophic and neuroprotective properties. NOT approved by FDA, EMA, or other Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western validation.
Dihexa
PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
DSIP
Delta Sleep Inducing Peptide, Delta Sleep-Inducing Peptide, WAGGDASGE
A nonapeptide discovered in 1977 that was initially thought to induce delta wave sleep. Research has shown broader neuromodulatory effects including stress-protection and analgesia, though its role as an endogenous sleep factor remains controversial.